Clinical trials: Prostate Specific Antigen
Prostate Carcinoma
Prostate Specific Antigen Levels of Individuals Living in Rural Areas
It was planned in cross-sectional design in order to determine the specific prostate antigen level and some characteristics and the relationship evaluations and prostate specific antigen formation in individuals living in rural…
- Trial name
- NCT06900348
- Testing
- PSA-Activated PSA-PAH1
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Suleyman Demirel University
Birth Control
Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom
This is a comparative, open-label two-period crossover study of up to 505 couples comparing the PATH Woman's Condom to the FC2 female condom.
- Trial name
- CONRAD-108 (NCT01178840)
- Testing
- WC then FC2, FC2 then WC
- Where
- United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- CONRAD
Prostate Cancer, Prostate Cancer, Familial
Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a
This study was designed to compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches for risk assessment of prostate cancer and for chemoprevention of prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer, Familial, Hereditary Prostate Cancer
- Trial name
- NCT02381015
- Testing
- Genetic Risk Score: Number Format, Genetic Risk Score: Number + Pictograph, Family History: Number Format
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Prostate Cancer
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
In Europe, prostate cancer (PCa) is the most common solid neoplasm, with an incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer.
- Trial name
- NCT01672411
- Where
- Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
The study aims to evaluate the detection rate and characteristics of prostate cancer among males with PSA values between 2.5 and 4.0 ng/mL in Nanjing, meanwhile, to access the effectiveness of conducting multi-parametric MRI…
- Trial name
- NCT04317625
- Testing
- mpMRI scanning
- Where
- China
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
MRI Versus PSA in Prostate Cancer Screening
In this open randomized controlled trial, we seek to study whether prostate cancer screening using multiparametric prostate magnetic resonance imaging (mpMRI) improves the detection rate of clinically-significant prostate cancer…
- Trial name
- MVP (NCT02799303)
- Testing
- Multi-parametric MRI, PSA testing
- Where
- Canada
- Volunteers
- 1,010 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Prostatic Diseases
Character Traits and Stress in Suspected Prostate Cancer
It has previously been reported that men with prostate cancer are 1 ) reduced quality of life after diagnosis and treatment, 2 ) neuroticism increases the reduction in QoL related to treatment side effects, and 3) often have very…
- Trial name
- NCT02031029
- Where
- 2 sites in Norway
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Prostate Cancer
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or…
- Trial name
- NCT03187990
- Testing
- [68Ga]PSMA-11, [18F]PSMA-1007
- Where
- Switzerland
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Irene Burger
Prostate Cancer
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm.
- Trial name
- ProScreen (NCT03423303)
- Testing
- Prostate cancer screening
- Where
- 2 sites in Finland
- Volunteers
- 17,400 people, healthy volunteers welcome
- Sponsor
- Tampere University
PSA, Prostate Cancer
Smart Prostate Specific Antigen (PSA) Screening Study
This intervention includes the introduction of the Prostate Cancer Working Group (PCWG )Smart PSA Screening Guidelines and implementation of patient navigation/ care coordination for men with elevated PSA (>4.0 ng/mL).
- Trial name
- NCT04782713
- Testing
- Completing surveys
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Prostate Cancer, Prostate Cancer Screening
Impact of PSA-based Screening on Mortality Among Men Aged 75-79: Target Trial Emulation
Opportunistic prostate-specific antigen (PSA) testing is widespread among men aged 75-79. Current American and European guidelines recommend PSA-based screening through shared decision-making if men are expected to live at least…
- Conditions
- Prostate Cancer, Prostate Cancer Screening, Prostate Cancer Screening Decision, Prostate Specific Antigen Screening
- Trial name
- NCT07206693
- Testing
- Prostate specific antigen (PSA)
- Where
- Sweden
- Volunteers
- 257,275 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Prostatic Neoplasms
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide.
- Trial name
- NCT04521894
- Testing
- Positron emission tomography/computerized tomography (PET/CT)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Prostate Cancer
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects…
- Trial name
- NCT03995888
- Testing
- rhPSMA-7.3 (18F) Injection
- Where
- Finland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Blue Earth Diagnostics